Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

A user plans to undergo a temporary MtF transformation to regrow hair, using estrogen, RU58841, and Dutasteride, then revert with testosterone. Many users criticize the plan, suggesting alternatives like hair transplants, and emphasize that estrogen is not a reliable solution for hair regrowth.

Red light therapy with dual wavelengths (650nm and 850nm) can stimulate hair regrowth without DHT blockers. Consistent use of a panel with these wavelengths has shown positive results in hair regrowth.

Tazarotene may outperform tretinoin for hairline treatment with minoxidil, but lacks evidence. Tretinoin is recommended for the scalp, while tazarotene can be used on the face.

PP405 was ineffective for hair growth as some follicles were already active before treatment, raising doubts about its efficacy. Users discussed other hair loss treatments like Minoxidil, finasteride, and RU58841, expressing skepticism and hope for future solutions.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

Microneedling may enhance hair loss treatment by increasing the effectiveness of topical minoxidil, especially for those lacking the necessary enzyme to activate it. It might also work by triggering growth factors and improving topical absorption.

Potential future hair loss treatments include stem cell therapy, Clascosterone (Breezula), Amplifica's signaling molecules, Botox, and dutasteride mesotherapy. Some treatments are promising but expensive, like Tsuji's technique, while others, like Botox, show unexpected results.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

A user discusses using tazarotene to enhance minoxidil's effectiveness for hair regrowth, believing it will make a significant difference. Others caution about potential risks of retinoids accelerating hair loss in some individuals.

PP405 may reactivate dormant hair follicles but won't replace hair transplants or resurrect dead follicles. Its effectiveness, cost, and impact compared to treatments like minoxidil and finasteride are uncertain.

17-alpha-estradiol may work for hair loss by inhibiting 5-alpha reductase, similar to finasteride. It might lower testosterone in the scalp, reducing DHT conversion.

Tretinoin may enhance the effectiveness of minoxidil for hair regrowth by increasing enzyme activity and skin permeability, but its standalone impact is limited. Some users experienced improved hair growth with tretinoin, while others found it worsened their condition.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

Stemson's presentation discussed using induced pluripotent stem cell technology to create new hair follicles for treating hair loss. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses preventing hair loss during detransitioning, with suggestions to use finasteride or dutasteride as DHT blockers. The user is also considering rosemary oil and monitoring testosterone levels.

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

A company is developing a topical dutasteride that targets hair follicles without significantly affecting systemic DHT levels, with trials underway to measure its effectiveness. Users discuss the potential benefits and skepticism around the formulation compared to existing treatments.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.